Plain-English translation of NCT06762730 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
When people with HIV start taking antiviral medications for the first time, their bones can sometimes become weaker. This trial is testing whether zoledronic acid—a medication given as a single injection—can help prevent this bone loss. Researchers want to see if this one-time treatment protects bone health during the first years of HIV care.
HIV antiviral medications are lifesaving, but they can cause bones to weaken, especially in newly diagnosed patients. Doctors want to find simple, effective ways to protect bone health without needing patients to take extra pills for years.
You likely qualify if…
You likely don't qualify if…
You'll visit the clinic multiple times over 4 years. At each visit, you'll have blood tests to check bone markers and bone density scans (a painless X-ray). Some participants will receive the medication injection within their first month of HIV treatment; others will be watched without the injection to compare results. You may also have dental and calcium screening to make sure the treatment is safe for you.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Israel
Phase
Post-approval monitoring
Sponsor
Hadassah Medical Organization
Collaborators
Sheba Medical Center, Rambam Health Care Campus
Enrollment target
~110 participants
Started
December 2024
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hila Doctor Elinav, Doctor
Hadassah University Medical center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.